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30UTR polymorphisms of HLA-GHuman Leukocyte Antigen (HLA)-G is involved in reprogramming immune responses at fetal-maternal
interface during pregnancy. We evaluated the genetic diversity of the 30 Un-Translated Region (UTR) of
HLA-G, previously associated with HLA-G mRNA post-transcriptional regulation, in women with unex-
plained Recurrent Pregnancy Loss (RPL), with 2 pregnancy losses (RPL-2, n = 28), or 3 or more pregnancy
losses (RPL-3, n = 24), and in 30 women with a history of successful pregnancy. Results showed in RPL-2,
but not in RPL-3, women compared to controls: i) higher frequency of the 14 bp Ins allele, in single and in
double copy; ii) significantly lower frequency of DelG/X genotype, iii) reduced frequency of the UTR-2,
and UTR-3 haplotypes; iv) higher frequencies of the UTR-5, UTR-7, and UTR-8 haplotypes. This pilot study
supports the relevance of performing 30UTR HLA-G genetic screening, not limited to a specific polymor-
phism, but considering the extended haplotypes, as a possible predictor of pregnancy outcome.
 2016 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Sporadic miscarriage is the most frequent complication of early
pregnancy. Approximately 70% of conceptions fail prior to live
birth with most losses occurring prior to implantation or before
the missed menstrual period [1]. Recurrent Pregnancy Loss (RPL)
was initially defined as three or more consecutive pregnancy losses
before 20–22 weeks of gestation [2]. Later, a large retrospective
study indicated no differences in the frequency of diagnostic fac-
tors between women with two or more pregnancy losses [3]. Based
on these results the Practice Committee of the American Society for
Reproductive Medicine defined RPL as two or more failed pregnan-
cies [4]. The prevalence of RPL is considerably lower than the
prevalence of sporadic miscarriage, ranging from 0.8–1.4% to
2–3%, if biochemical losses (i.e. pregnancies that fail before ultra-
sound or histologic confirmation) are included [5]. Causes of RPL
include chromosomal abnormalities, autoimmunity, such as
untreated hypothyroidism and diabetes mellitus, uterine anatomicabnormalities, heritable thrombophilia, infections, and environ-
mental cues [6]. The incidence of fetal chromosomal abnormalities,
which is identified in 29–60% of women with RPL, decreases as the
number of miscarriages increases, suggesting that other mecha-
nisms may play a role in pregnancy loss [7]. The correction of
endocrine disorders, and the treatment of the anti-phospholipid
syndrome (APS), the most common autoimmune cause of preg-
nancy complications, have been shown to be effective in control-
ling miscarriage [6]. However, prevention of RPL remains an
unmet medical need.
The uterus and the placenta constitute a unique site of immune
modulation where the semi-allogeneic fetus is tolerated by the
maternal immune system. Several years of research have identified
the non-classical Human Leukocyte Antigen (HLA)-G, physiologi-
cally expressed on extravillous trophoblasts [8], as a molecule
operatives in promoting tolerance during pregnancy [9]. HLA-G
inhibits cytotoxic CD8+ T cells and natural killer (NK) cells, and
allo-specific CD4+ T cell proliferation, modulates the activity of
antigen presenting cells (APCs), and induces the differentiation of
myeloid and T regulatory cells (reviewed in [10]). At the fetal
maternal inferface during pregnancy the expression of HLA-G on
trophoblasts prevents their NK-mediated lysis [11], and HLA-G-
Table 1
Patients characteristics and pregnancy history.
RPL-2 women RPL-3 women HP women
Patients (N) 28/52 24/52 30
Age (mean ± SD) 36.3 ± 4.3 36.5 ± 4.3 36.1 ± 4.0
Caucasian (N, %) 26/28 (92.8) 22/24 (91.7) 27 (90)
Miscarriages (N, %) 57/69 (82.6) 92/112 (82.1) 0
Intrauterine fetal death (N, %) 1/69 (1.4) 1/112 (0.9) 0
Live birth (N, %) 11/69 (16) 19/112 (17) 38 (100)
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[12,13], supporting the critical role of HLA-G in promoting toler-
ance during pregnancy. In pregnancy complications, such as pre-
eclampsia, it has been repetitively demonstrated a reduced levels
of HLA-G expression in placental tissues [14,15] and in the mater-
nal circulation [15,16], and defects in HLA-G-expressing regulatory
cells [13]. Moreover, in RPL reduced levels of HLA-G have been
reported [17].
The HLA-G locus contains several polymorphisms in the non-
coding regions, including those present at the 30Un-Translated
Region (UTR), which influence HLA-G expression [18]. Among the
30UTR of HLA-G polymorphisms, the most studied are an inser-
tion/deletion (Ins/Del) of 14 base pairs (bp) that has been associ-
ated with HLA-G mRNA stability [19,20], the G/C in position
+3142 that can be involved in micro(mi)RNA-mediated post-
transcriptional regulation [21], and the G/A at position +3187 that
lands in an AU-rich region [22]. Other and less studied Single
Nucleotide Polymorphisms (SNPs) are +3001 C/T, +3003 T/C,
+3010 G/C, +3027 C/A, +3035 C/T, and +3196 C/G, which have been
proposed as potential miRNA binding sites [23]. These polymor-
phisms arrange in haplotypes, named UTRs [18], and the most fre-
quent are from UTR-1 to UTR-8 [24]. The association between
30UTR haplotypes of HLA-G and protein expression has been
recently studied: haplotypes containing 14 bp Del (i.e. UTR-1) are
associated with high levels of soluble HLA-G, whereas those with
14 bp Ins (i.e. UTR-2, and UTR-5) with low HLA-G levels [25].
A lot of efforts have been made to define whether the genetic
variations influencing the HLA-G expression can be associated with
tolerance and/or pregnancy complications. Several studies have
been conducted to define the influence of the 14 bp Ins/Del in
recurrent miscarriage (RSA) with contrasting results [26–28].
Recent meta-analysis studies attributed the variability in the
reported results to the heterogeneity of the cohorts analyzed and
to the criteria used for patient selection [29,30]. Nevertheless,
Wang et al. [29] reported an association between the 14 bp Ins
with recurrent miscarriage and an overall risk of RSA indepen-
dently from the number of pregnancy losses, while Fan et al. [30]
reported the same association only in women with three or more
miscarriages. Thus far, the association between 30UTR polymor-
phisms, not limited to the 14 bp Ins/Del, or the extended 30UTR
HLA-G haplotypes and RPL has been not investigated.2. Subjects and methods
2.1. Study subjects
Subjects recruited in the study were admitted to the High-risk
Pregnancy Outpatients Clinics of the San Raffaele University
Hospital, Milan, Italy for investigation and treatment. The study
sample included 52 patients diagnosed with RPL as two or more
consecutive pregnancy losses confirmed by the Hospital records,
according with the definition of the American Society for
Reproductive Medicine [4]. Patients were subsequently divided in
two different groups: women with 2 pregnancy losses (RPL-2,
n = 28), and women with 3 or more pregnancy losses (RPL-3,
n = 24). The control group comprised 30 age-matched women from
couples with no history of miscarriages and a previous history of
successful pregnancy (HP) (Table 1). Among the RPL group 28.8%
had signs of autoimmunity, 15.4% had dysthyroidism, 1.9% had
hypertension, and 17.3% had congenital thrombophilia, and none
of them had uterine abnormalities as assessed by hysteroscopy
or uterine ultrasonography. Conversely, 26.7% of HP had uterine
anatomic abnormalities and after correction delivered successfully,
and none of them was affected by other diseases. All RPL patients
and their male partners had normal karyotypes. No othersinvestigations on the male partners were performed. All patients
were regularly menstruating and all had normal thyroxin levels
in the plasma. Human peripheral blood was obtained upon
informed consent in accordance with local ethical committee
approval and with the Declaration of Helsinki.
2.2. DNA isolation
Genomic DNA was isolated from peripheral blood mononuclear
cells (PBMCs), separated by density gradient centrifugation over
Lymphoprep (Nycomed Amersham), using a commercial kit
(QIAamp, QIAGEN, Italy) according to the manufacturer’ s instruc-
tions. The DNA samples were stored at 20 C in a freezer
compartment.
2.3. Amplification and sequencing of 30UTR of the HLA-G gene (or
genotyping)
100 ng of genomic DNA were amplified in a 25 ll reaction con-
taining 1 polymerase chain reaction (PCR) buffer (Roche, USA),
0.2 mM dNTP mix (Roche, USA), 1.5 mM MgCl2 (Roche, USA), 0.8
U Taq Polymerase (Roche, USA), and 1 lM of each primer (For: 50
TCACCCCTCACTGTGACTGA 30; Rev: 50 TTCTCATGTCTTCCATT-
TATTTTGTC 30). The initial denaturation step was carried out at
95 C for 3 min, followed by 30 cycles at 93 C for 60 s, 58 C for
60 s, 72 C for 60 s, and by a final extension step at 72 C for
10 min. The amplification product was evaluated using a 2.5% agar-
ose gel, purified using a commercial kit (Wizard SV Gel and PCR
Clean-Up System, Promega, WI, USA) according to the manufac-
turer’ s instructions. The Rev primer (50 TTCTCATGTCTTCCATT-
TATTTTGTC 30) by PrimmBiotech (Milan, Italy) was used to
perform direct sequencing on both strands of purified amplifica-
tion products. Sequencing pherograms were analyzed with the
CodonCode Aligner software (Centerville, MA), and the 14 bp
Ins/Del (rs1704), +3003 C/T (rs1707), +3010 C/G (rs1710), +3027
A/C (rs17179101), +3035 C/T (rs17179108), +3142 C/G
(rs1063320), +3187 A/G (rs9380142) and +3196 C/G (rs1610696)
polymorphic sites were individually annotated. Haplotype and
genotype construction were assigned and named according to pre-
vious report [24] (Supplementary Table 1).
2.4. Statistical analysis
HLA-G 30UTR allele and genotype frequencies were obtained by
direct count. Single comparisons of allele and genotype frequencies
between populations were performed using the Fisher test and,
when necessary, Bonferroni correction for multiple comparisons
was applied. Differences were regarded as significant at *P < 0.05.
The results were analyzed using GraphPad Prism 5.0 (GraphPad
Software, Inc. La Jolla, CA).
3. Results and discussion
The main objective of this pilot study was to investigate the
possible association of 30UTR polymorphisms and haplotypes of
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losses (RPL, n = 52). RPL subjects were subgroups in women with 2
pregnancy losses (RPL-2, n = 28) and women with 3 or more preg-
nancy losses (RPL-3, n = 24). As control we used a cohort of age-
matched women from couples with no history of miscarriages
(HP, n = 30) (Table 1).
We analyzed 8 out of the 16 polymorphisms previously
described at the 30UTR of HLA-G [18]: the 14 bp Ins/Del (rs1704),
+3003 C/T (rs1707), +3010 C/G (rs1710), +3027 A/C
(rs17179101), +3035 C/T (rs17179108), +3142 C/G (rs1063320),
+3187 A/G (rs9380142) and +3196 C/G (rs1610696). Although no
statistically significant differences were observed, we found that
the 14 bp Ins allele that has been associated with low HLA-G pro-
tein levels [31] was more represented in RPL-2 compared to HP
women both in single (50% vs. 35%) and in double (25% vs. 10%)Table 2
Estimated allele and genotype frequencies observed at HLA-G 30UTR polymorphic sites in
Polymorphisms RPL-2 (N = 28) Freq (%) RPL-3 (N = 24)
14 bp
Ins 28 50 20
Del 28 50 28
Ins/Ins 7 25 4
Del/Del 7 25 7
Ins/Del 14 50 13
+3003
C 10 18 6
T 46 82 42
C/C 0 0 1
T/T 18 64 19
C/T 10 36 4
+3010
C 26 46.5 22
G 30 53.5 26
C/C 8 28 7
G/G 10 36 9
C/G 10 36 8
+3027
A 4 7 2
C 52 93 46
A/A 0 0 0
C/C 24 86 22
A/C 4 14 2
+3035
C 47 84 44
T 9 16 4
C/C 19 68 20
T/T 0 0 0
C/T 9 32 4
+3142
C 25 45 20
G 31 55 28
C/C 5 19 4
G/G 8 28 8
C/G 15 53 12
+3187
A 42 75 35
G 14 25 13
A/A 14 50 11
G/G 0 0 0
A/G 14 50 13
+3196
C 38 68 34
G 18 32 14
C/C 12 43 11
G/G 2 7 1
C/G 14 50 12
P2 = Comparison between RPL with 2 pregnancy losses (RPL-2) and HP using Fisher’s tes
P3 = Comparison between RPL with 3 or more pregnancy losses (RPL-3) and HP using Fi
⁄ = Statistical significance was lost after Bonferroni correction for multiple comparisons
Bold values are significant values obtained comparing RPL-2 versus HP women.copy (Table 2). Conversely, the 14 bp Del/Del genotype that has
been associated with high levels of soluble HLA-G [32] was more
represented in HP compared to RPL-2 women (37% vs. 25%;
Table 2). No major differences were observed in the frequencies
of the 14 bp Ins allele and of the 14 bp Ins/Ins genotype between
RPL-3 and HP women (Table 2). Our data are partially consistent
with those reported by Wang et al. [29], indicating the association
of the 14 bp Ins with an increased risk of recurrent miscarriage.
Conversely, the lack of association between 14 bp Ins with recur-
rent miscarriage in women with 3 or more pregnancy losses is in
contrast to Fan et al. [30]. It cannot be excluded that this discrep-
ancy can be attributed to the low number of women included in
the present study.
As reported in Table 2, among other 30UTR polymorphisms ana-
lyzed we observed a significant lower frequency of the +3035 CRPL and HP women.
Freq (%) HP (N = 30) Freq (%) P2 P3
44 21 35 0.1327 0.5511
56 39 65
17 3 10 0.1729 0.6868
29 11 37 0.4022 0.7720
54 16 53 1.0000 1.0000
12.5 6 10 0.2843 0.7629
87.5 54 90
4 1 3 1.0000 1.0000
79 25 84 0.1362 0.7363
17 4 13 0.0667 1.0000
46 32 53 0.5774 0.5615
54 28 47
29 8 27 1.0000 1.0000
37.5 7 23 0.3902 0.3695
33.5 15 50 0.3012 0.2738
4 1 2 0.1953 0.5838
96 59 98
0 0 0 – –
92 29 97 0.1866 0.5791
8 1 3 0.1866 0.5791
92 58 97 0.0258⁄ 0.4032
8 2 3
83 28 93 0.0190⁄ 0.3890
0 0 – –
17 2 7 0.0190⁄ 0.3890
42 25 42 0.8515 1.0000
58 35 58
17 3 10 0.4637 0.6868
33 8 27 1.0000 0.7653
50 19 63 0.5945 0.4098
73 42 70 0.6781 0.8317
27 18 30
46 14 46.5 1.0000 1.0000
0 2 7 0.4918 0.4969
54 14 46.5 1.0000 0.7846
71 43 72 0.6896 1.0000
29 17 28
46 14 46.5 0.7976 1.0000
4 2 7 1.0000 1.0000





Estimated genotype frequencies observed at HLA-G 30UTR polymorphic sites in RPL and HP women.
Polymorphisms RPL-2 (N = 28) Freq (%) RPL-3 (N = 24) Freq (%) HP (N = 30) Freq (%) P2 P3
14 bp/+3142
InsG/InsG 7 25 4 17 3 10 0.1729 0.6868
DelC/DelC 5 18 5 21 4 13 0.7260 0.4542
InsG/DelC 13 46 8 33 10 33.5 0.4214 0.7654
DelG/X 3 11 7 29 13 43.5 0.0078/0.0312⁄ 0.7688
P2 = Comparison between RPL with 2 pregnancy losses (RPL-2) and HP using Fisher’s test.
P3 = Comparison between RPL with 3 or more pregnancy losses (RPL-2) and HP using Fisher’s test.
⁄ = Statistical significance calculated with/without Bonferroni correction for multiple comparisons.
Bold values are significant values obtained comparing RPL-2 versus HP women.
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P = 0.0258) and in double copy (68% vs. 93%, P = 0.0190), but not
between RPL-3 and the control group. Notably, the statistical sig-
nificance was lost when we applied the Bonferroni correction
(P = 0.2064 and P = 0.152, respectively).
The 14 bp polymorphism is in strong linkage disequilibrium
with the +3142 C/G SNP that can be involved in HLA-G post-
transcriptional regulation being the target of miR-148a, miR-
148b, and miR-152 [21]. Of note, 14 bp Ins is always associated
with +3142 G [33]. We therefore evaluated the genetic frequencies
of the following combinations: InsG/InsG, DelC/DelC, InsG/DelC,
and DelG/X. Results showed a higher, but not statistically signifi-
cant, frequency of the InsG/InsG genotype in the RPL-2 compared
to HP women (25% vs. 10%, P = 0.1729; Table 3). Moreover, a signif-
icantly lower frequency of DelG/X genotype was detected in RPL-2
compared to HP women (11% vs. 43.5%, P = 0.0078, and P = 0.0312
with Bonferroni correction; Table 3). Similarly, the frequency of the
DelG/X genotype in the RPL-3 group was lower, but not statistical
significant, compared to HP women (29% vs. 43.5%). No differences
in the frequencies of DelC/DelC and InsG/DelC were observed nei-
ther in the RPL-2 nor in the RPL-3 compared to the HP (Table 3).
We next investigated the proportion of the most frequent
extended 30UTR haplotypes of HLA-G (from UTR-1 to UTR-8) inTable 5
Estimated allelic frequencies of 30UTR haplotypes of HLA-G in RPL and HP women.
Haplotypes RPL-2 (N = 28) Freq (%) RPL-3 (N = 2
14 bp Del UTR-1 14 50 13
UTR-4-6 11 39 8
UTR-3 3 11 7
14 bp Ins UTR-2 13 46 9
UTR-5-7-8 15 54 11
P2 = Comparison between RPL with 2 pregnancy losses (RPL-2) and HP using Fisher’s tes
P3 = Comparison between RPL with 3 or more pregnancy losses (RPL-3) and HP using Fi
⁄ = Statistical significance was lost after Bonferroni correction for multiple comparisons
Bold values are significant values obtained comparing RPL-2 versus HP women.
Table 4
Estimated haplotype frequencies observed at HLA-G 30UTR polymorphic sites in RPL and H
Haplotypes RPL-2 (N = 28) Freq (%) RPL-3 (N = 24)
UTR-1 14 25 13
UTR-2 13 23 9
UTR-3 3 5 7
UTR-4 9 16 5
UTR-5 5 9 3
UTR-6 2 4 3
UTR-7 4 7 3
UTR-8 6 11 5
P2 = Comparison between RPL with 2 pregnancy losses (RPL-2) and HP using Fisher’s tes
P3 = Comparison between RPL with 3 or more pregnancy losses (RPL-3) and HP using Fi
⁄ = Statistical significance was lost after Bonferroni correction for multiple comparisons
Bold values are significant values obtained comparing RPL-2 versus HP women.RPL and HP women. In line with previous data [18,34], UTR-1
and UTR-2 resulted to be the most represented haplotypes in our
cohorts of women (Table 4). UTR-3 (Del/+3003T/+3010C/+3027C/
+3035C/+3142G/3187A/+3196G), which has been associated with
intermediate/high levels of soluble or membrane-bound HLA-G
[25,35], was significantly less frequent in RPL-2 compared to HP
women (P = 0.0078), but by applying the Bonferroni correction,
the statistical significance was lost (P = 0.0624). Although no statis-
tically significant differences were observed, a higher frequency of
UTR-5 (Ins/+3003T/+3010C/+3027C/+3035T/+3142G/3187A/+3196
C), UTR-7 (Ins/+3003T/+3010C/+3027A/+3035T/+3142G/3187A/+3
196C), and UTR-8 (Ins/+3003T/+3010G/+3027C/+3035C/+3142G/3
187A/+3196G) were observed in both RPL-2 and RPL-3 compared
to women with successful pregnancy (Table 4). We next subdi-
vided haplotypes into two sub-groups according to the presence
of the 14 bp Ins (UTR-2, -5, -7 and -8) or Del (UTR-1, -3, -4 and -
6) (Table 5). Among the 14 bp Del haplotypes, UTR-3 was signifi-
cantly less represented in RPL-2 compared to HP women
(P = 0.0240) (Table 5). Within the 14 bp Ins haplotypes, a signifi-
cantly lower frequency of UTR-2 compared to UTR-5, UTR-7, and
UTR-8 was found in RPL-2 compared to HP women (46% vs. 76%,
P = 0.0448), but by applying the Bonferroni correction, the
statistical significance was lost. This result is particularly relevant4) Freq (%) HP (N = 30) Freq (%) P2 P3
46 18 46 0.8076 1.0000
29 7 18 0.0920 0.3777
25 14 36 0.0240⁄ 0.4276
45 16 76 0.0448⁄ 0.0578





Freq (%) HP (N = 30) Freq (%) P2 P3
27 18 30 0.6781 0.8317
19 16 27.5 0.8304 0.3671
15 14 23 0.0078⁄ 0.3300
10.5 6 10 0.4108 1.0000
6 1 1.5 0.1051 0.3209
6 1 1.5 0.6089 0.3209
6 1 1.5 0.1953 0.3209
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represented haplotype in the worldwide population, whereas
UTR-5, UTR-7, and UTR-8 haplotypes are normally found at low
frequencies [18,34]. The UTR-2, UTR-5, UTR-7, and UTR-8 have in
common 14 bp Ins, +3142G and +3187A, which have been individ-
ually associated with low HLA-G mRNA levels [36]. However, they
differ in +3010 C/G, +3027 C/A, +3035 C/T, and +3196 C/G, suggest-
ing that these polymorphisms may be also important in modulat-
ing the expression levels of HLA-G. In line with this hypothesis are
results in which the presence of UTR-5 and UTR-7 haplotypes has
been associated with low levels of soluble HLA-G, whereas UTR-2
with intermediate levels [25].
In conclusion, in this pilot study we analyzed for the first time
the extended 30UTR HLA-G haplotypes in women experienced
RPL. Our results suggested an association of specific 30UTR haplo-
types of HLA-G with 2 consecutive, but not with 3 or more, preg-
nancy losses, although the statistical significance was not always
reached. We cannot exclude that enlarging the cohorts of women
we may strengthen the associations. Although more comprehen-
sive study, in which the evaluation of other HLA-G gene segments,
such as the promoter and the coding region, may help in the study
of the expression of HLA-G, this study confirms the important role
of HLA-G in pregnancy. Moreover, these findings support the rele-
vance and foster the importance of performing 30UTR HLA-G
genetic screening, not limited to a specific polymorphism, but con-
sidering the extended haplotypes, as a predictor of pregnancy
outcome.
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